Trial Search Results

Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme

The purpose of this study is to determine the safety and effectiveness of Azixa in patients with recurrent glioblastoma multiforme

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Myrexis Inc.

Stanford Investigator(s):


  • Drug: Azixa


Phase 2


Inclusion Criteria:

   - Have histologically proven malignant Glioblastoma Multiforme in first or second

   - Have failed prior Fractionated External Beam Cranial Irradiation or IMRT

   - Be at least 18 years old and with a life expectancy ≥ 8 weeks or ≥ 4 weeks if failed
   prior Avastin therapy

   - Have a Karnofsky performance status of ≥ 60

   - Have adequate bone marrow function, liver function, and renal function before starting

Exclusion Criteria:

   - Have had more than two relapses

   - Have had radiosurgery

   - Have a cardiac ejection fraction < 50% by MUGA or ECHO

   - Have Troponin-I elevated above the normal range

   - Have an increasing steroid requirement

   - Have MRI evidence at baseline of enlarging or clinically significant intratumor

   - Have active stroke and/or transient ischemic attack not optimally managed

   - Have active cardiovascular disease (e.g. sub-optimally managed angina, impending
   myocardial infarction, or uncontrolled hypertension)

   - Be pregnant or breast feeding

   - Have had prior hypersensitivity reaction to Cremophor EL

   - Be HIV positive

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
Not Recruiting